News Formal

Weight loss drug contender Zealand Pharma jumps 18% on trial results

  • 📰 CNBC
  • ⏱ Reading Time:
  • 38 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 42%
  • Publisher: 72%

Pharmaceuticals News

Markets,Breaking News: Markets,Zealand Pharma A/S

The Danish company is testing a rival to drugs such as Ozempic and Wegovy that it says may deliver a 'better patient experience.'

Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide.

Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024.popped on Friday, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. The company said Thursday that a course of 16 weekly high doses of long-acting amylin analog petrelintide reduced body weight by up to 8.6% on average in the study. A placebo drug led to a body weight decrease of 1.7%.Petrelintide was "judged to be safe and well tolerated at all dose levels," and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Weight loss drug contender Zealand Pharma jumps 23% on trial resultsThe Danish company is testing a rival to drugs such as Ozempic and Wegovy which it says may deliver a “better patient experience.”
Source: nbcchicago - 🏆 545. / 51 Read more »